BIOGEN ADVANCES SPINAL MUSCULAR ATROPHY (SMA) CLINICAL RESEARCH WITH NEW STUDY EVALUATING A HIGHER DOSE OF SPINRAZA (NUSINERSEN) AND ADDITIONAL DATA IN A BROAD RANGE OF PATIENTS
[caption id="attachment_9277" align="aligncenter" width="747"] Press Release[/caption]
September 18, 2019 at 7:30 AM EDT
- DEVOTE trial to evaluate safety and even greater efficacy of a higher dose of SPINRAZA in the treatment of SMA; well-established safety profile supports exploration of potential benefits
- Long-term data from the SHINE study demonstrate improvements in or stabilization of motor function in patients as old as 21 treated with SPINRAZA for up to nearly six years
MEDIA CONTACT: Biogen David Caouette + 617 679 4945 public.affairs@biogen.com | INVESTOR CONTACT: Joe Mara +1 781 464 2442 IR@biogen.com | |